ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies designed to block the CD47 immune checkpoint pathway for cancer treatment.
No data available
Are you interested in the impact of this company or this ETF?
It seems we haven't collected any data here yet. Just let us know and we will try to find data as soon as possible. Thank you for your feedback!